Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Department of Justice
Cantor Fitzgerald
Mallinckrodt
Covington
Farmers Insurance
Argus Health
Express Scripts
McKinsey

Generated: July 17, 2018

DrugPatentWatch Database Preview

Dolasetron mesylate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for dolasetron mesylate and what is the scope of dolasetron mesylate patent protection?

Dolasetron mesylate
is the generic ingredient in one branded drug marketed by Us Pharm Holdings and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for dolasetron mesylate. One supplier is listed for this compound.
Pharmacology for dolasetron mesylate
Synonyms for dolasetron mesylate
(2,6,8,9a)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1Hindole-3-carboxylate monomethanesulfonate, monohydrate
(2alpha,6alpha,8alpha,9abeta)-octahydro-3-oxo-2,6-methano-2h-quinolizin-8-yl-1h-indole-3-carboxylate
(2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate monomethanesulfonate
(2R,6R,8R,9aS)-3-oxooctahydro-2H-2,6-methanoquinolizin-8-yl 1H-indole-3-carboxylate
(5S,6R,8R,9aS)-3-Oxooctahydro-1H-2,6-methanoquinolizin-8-yl 1H-indole-3-carboxylate methanesulfonate
115956-12-2
115956-13-3
2886AH
3-Oxooctahydro-2,6-methano-2H-quinolizin-8-yl 1H-indole-3-carboxylate methanesulfonate
3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate
3594AH
878143-33-0
956D133
AB00698337-03
AC1MHWDA
AC1MHWDD
AJ-62451
AK104158
AKOS015895201
AKOS022184758
AKOS025404537
AKOS030526960
AKOS030573291
Anemet
Anzemet
Anzemet (TN)
Anzemet Cinv
Anzemet hydrate
API0002473
AS-13228
BDBM50451546
BIDD:GT0287
C-22341
C19H20N2O3.CH4O3S
C19H20N2O3.CH4O3S.H2O
CAS-115956-13-3
CCG-101131
CCG-220885
CCG-222446
CHEBI:94561
CHEMBL2368924
CHEMBL2368925
CHEMBL2373322
CPD000469228
CS-3746
CS-3747
CS-3748
D00YLW
Dalasetron (Mesylate hydrate)
Dalasetron (Mesylate)
Dalasetron Mesylate
Dalasetron Mesylate Hydrate
DB00757
dolasetron
Dolasetron (INN)
Dolasetron (Mesylate hydrate)
Dolasetron (Mesylate)
Dolasetron [INN:BAN]
Dolasetron mesilate
Dolasetron mesylate hydrate
Dolasetron mesylate hydrate, >=98% (HPLC), powder
DOLASETRON MESYLATE MONOHYDRATE
Dolasetron methanesulfonate hydrate
Dolasetronum
Dolasetronum [INN-Latin]
Dolasteron
DSSTox_CID_26827
DSSTox_GSID_46827
DSSTox_RID_81939
DTXSID3046827
DTXSID4048276
H668
HMS2052I17
HY-B0750
HY-B0750A
HY-B0750B
KB-50417
MDL-73147EF
MLS001424160
MolPort-023-220-279
MolPort-039-101-338
NC00381
NCGC00181048-01
Q-100996
Q-101000
QTFFGPOXNNGTGZ-LIFGOUTFSA-N
SAM001246842
SCHEMBL1237588
SCHEMBL41145
SCHEMBL42063
SCHEMBL42064
SMR000469228
ST51052740
Tox21_112695
UKTAZPQNNNJVKR-KJGYPYNMSA-N
ZINC100019093
ZINC100038399
ZINC103105084
ZINC2688

US Patents and Regulatory Information for dolasetron mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-001 Sep 11, 1997 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for dolasetron mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-001 Sep 11, 1997 ➤ Sign Up ➤ Sign Up
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 ➤ Sign Up ➤ Sign Up
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 ➤ Sign Up ➤ Sign Up
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
US Army
Healthtrust
AstraZeneca
Covington
Merck
Chinese Patent Office
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.